#	Pagina
attuale pagina	/open-h2020/projects/223199/index.html
-1	/open-h2020/projects/218514/index.html

Opendata, web and dolomites

VASA SIGNED

Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in adults in endemic areas of sub-Saharan Africa

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

VASA project word cloud

Explore the words cloud of the VASA project. It provides you a very rough idea of what is the project "VASA" about.

mansoni billion refine sm causing consistently adults mass requiring compromised baboon se schistosoma techniques expression burden forms species tropical effectiveness pathology cgmp 74 resolving model immune regular elimination data impacting programs project signatures downstream madagascar reg constraints schistosome burkina potent global request egg site treatment science adjuvant efficacy anti antibodies requested re healthy manufacturer intestinal lasting blocking chemotherapy infections endemic correlates fecundity candidate ranked disease urinary p80 people poverty resource antigengla prevention gene schistosomiasis manufacturing vaccine transfer epidemiological settings capacity efficacious therapeutic exhibited safety faso transmission reinfection preferred innate poor urgently transferred adaptive vaccines prophylactic clinical immunogenicity gmp haematobium diagnostic hepatic protection schistoshield human african countries

Project "VASA" data sheet

The following table provides information about the project.

Coordinator	THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE Organization address address: TRINITY LANE THE OLD SCHOOLS city: CAMBRIDGE postcode: CB2 1TN website: www.cam.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Total cost	0 €
EC max contribution	6˙619˙342 € (0%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Two-Stage-RTD
Funding Scheme	RIA-LS
Starting year	2019
Duration (year-month-day)	from 2019-06-01 to 2024-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE Organization address address: TRINITY LANE THE OLD SCHOOLS city: CAMBRIDGE postcode: CB2 1TN website: www.cam.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CAMBRIDGE)	coordinator	1˙537˙385.00
2	INTERNATIONAL VACCINE INSTITUTE INTERNATIONAL VACCINE INSTITUTE Organization address address: San 4-8 Bongcheon-7 dong, Kwanak gu city: Seoul postcode: 151919 website: www.ivi.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	KR (Seoul)	participant	1˙217˙823.00
3	UNIVERSITY OF ANTANANARIVO UNIVERSITY OF ANTANANARIVO Organization address address: Campus d'Ankatso city: Antananarivo postcode: 101 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	MG (Antananarivo)	participant	864˙420.00
4	TEXAS TECH UNIVERSITY SYSTEM TEXAS TECH UNIVERSITY SYSTEM Organization address address: 1508 KNOXVILLE AVENUE city: LUBBOCK postcode: 79409 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (LUBBOCK)	participant	704˙831.00
5	GROUPE DE RECHERCHE ACTION EN SANTE SARL GROUPE DE RECHERCHE ACTION EN SANTE SARL Organization address address: SECTEUR 25 SOMGANDE RUE 25 26 PORTE 79 city: OUAGADOUGOU postcode: 6 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BF (OUAGADOUGOU)	participant	643˙812.00
6	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	612˙856.00
7	PAI LIFE SCIENCES INC. PAI LIFE SCIENCES INC. Organization address address: 251 LITTLE FALLS DRIVE city: WILMINGTON postcode: 19808 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (WILMINGTON)	participant	387˙290.00
8	GOETEBORGS UNIVERSITET GOETEBORGS UNIVERSITET Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 website: www.gu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (GOETEBORG)	participant	350˙000.00
9	UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO Organization address address: . city: OUAGADOUGOU 03 postcode: 3 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BF (OUAGADOUGOU 03)	participant	259˙672.00
10	EBERHARD KARLS UNIVERSITAET TUEBINGEN EBERHARD KARLS UNIVERSITAET TUEBINGEN Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 website: www.uni-tuebingen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (TUEBINGEN)	participant	41˙250.00

Map

Project objective

Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries. Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed. Chemotherapy is the preferred method for schistosomiasis control; but the effectiveness of mass-treatment programs is compromised by reinfection requiring regular re-treatment. An efficacious vaccine, with long-lasting protection against all schistosomiasis forms, would impact disease control. We request funding for the clinical development of our SchistoShield®-vaccine (Sm-p80 antigenGLA-SE adjuvant) in Burkina Faso and Madagascar, where Schistosoma mansoni (causing intestinal/hepatic schistosomiasis) and S. haematobium (causing urinary schistosomiasis) are endemic. In baboon studies, SchistoShield® has been effective against all major schistosome species. It is the only vaccine candidate having consistently exhibited potent prophylactic, anti-fecundity, egg-induced pathology resolving, transmission-blocking and therapeutic efficacy. The objectives are to 1) transfer vaccine manufacturing technology for cGMP production to a European manufacturer; 2) assess the safety/immunogenicity of SchistoShield® in a Phase I clinical study in healthy African adults; 3) refine a schistosomiasis human challenge model to identify correlates of protection, innate and adaptive immune signatures, gene expression and the role of antibodies in the prevention/control of Schistosoma infections; and 4) foster a global consortium to advance research on schistosomiasis vaccines and address downstream access constraints in resource-poor settings. The funding requested will allow the clinical development of SchistoShield®. GMP production will be transferred to a European partner. African site research capacity will be improved and epidemiological burden data using novel diagnostic techniques will be used to advance clinical development to Phase 2 and potential future elimination project

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VASA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VASA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More